Literature DB >> 11359819

Induction of telomerase activity during development of human mast cells from peripheral blood CD34+ cells: comparisons with tumor mast-cell lines.

C Chaves-Dias1, T R Hundley, A M Gilfillan, A S Kirshenbaum, J R Cunha-Melo, D D Metcalfe, M A Beaven.   

Abstract

To further characterize the development of mast cells from human hemopoietic pluripotent cells we have investigated the expression of telomerase activity in cultured human peripheral blood CD34+ cells, and CD34+ /CD117+ /CD13+ progenitor mast cells selected therefrom, with the idea that induction of telomerase is associated with clonal expansion of CD34+ /CD117+ /CD13+ cells. A rapid increase in telomerase activity preceded proliferation of both populations of cells in the presence of stem cell factor and either IL-3 or IL-6. The induction was transient, and telomerase activity declined to basal levels well before the appearance of mature mast cells. Studies with pharmacologic inhibitors suggested that this induction was initially dependent on the p38 mitogen-activated protein kinase and phosphatidylinositol 3'-kinase, but once cell replication was underway telomerase activity, but not cell replication, became resistant to the effects of inhibitors. Tumor mast cell lines, in contrast, expressed persistently high telomerase activity throughout the cell cycle, and this expression was unaffected by inhibitors of all known signaling pathways in mast cells even when cell proliferation was blocked for extended periods. These results suggest that the transient induction of telomerase activity in human progenitor mast cells was initially dependent on growth factor-mediated signals, whereas maintenance of high activity in tumor mast cell lines was not dependent on intracellular signals or cell replication.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11359819     DOI: 10.4049/jimmunol.166.11.6647

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

Review 1.  Genetic and epigenetic trends in telomere research: a novel way in immunoepigenetics.

Authors:  Dora Melicher; Edit I Buzas; Andras Falus
Journal:  Cell Mol Life Sci       Date:  2015-07-20       Impact factor: 9.261

2.  mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.

Authors:  Daniel Smrz; Mi-Sun Kim; Shuling Zhang; Beverly A Mock; Sárka Smrzová; Wendy DuBois; Olga Simakova; Irina Maric; Todd M Wilson; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Blood       Date:  2011-11-03       Impact factor: 22.113

3.  Examination of the role of TRPM8 in human mast cell activation and its relevance to the etiology of cold-induced urticaria.

Authors:  Nevenka Medic; Avanti Desai; Hirsh Komarow; Lauranell H Burch; Geethani Bandara; Michael A Beaven; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Cell Calcium       Date:  2011-09-08       Impact factor: 6.817

4.  Kit- and Fc epsilonRI-induced differential phosphorylation of the transmembrane adaptor molecule NTAL/LAB/LAT2 allows flexibility in its scaffolding function in mast cells.

Authors:  Shoko Iwaki; Jiri Spicka; Christine Tkaczyk; Bettina M Jensen; Yasuko Furumoto; Nicolas Charles; Martina Kovarova; Juan Rivera; Vaclav Horejsi; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Cell Signal       Date:  2007-10-16       Impact factor: 4.315

5.  Synergistic activation of phospholipases Cgamma and Cbeta: a novel mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast cell mediator release.

Authors:  Hye Sun Kuehn; Michael A Beaven; Hong-Tao Ma; Mi-Sun Kim; Dean D Metcalfe; Alasdair M Gilfillan
Journal:  Cell Signal       Date:  2008-01-22       Impact factor: 4.315

6.  Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.

Authors:  Geethani Bandara; Rosa Muñoz-Cano; Araceli Tobío; Yuzhi Yin; Hirsh D Komarow; Avanti Desai; Dean D Metcalfe; Ana Olivera
Journal:  Front Immunol       Date:  2018-03-28       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.